Social contract theory and just decision making: Lessons from genetic testing for the BRCA mutations

Kennedy Institute of Ethics Journal

Volumn 14, Issue 2, 2004, Pages 115-142

  Williams Jones, Bryn ^b   Burgess, Michael M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOMERTON COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONSULTATION; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMIC ASPECT; FAMILY HISTORY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH BEHAVIOR; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH EDUCATION; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; LAW; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL INFORMATION; MUTATIONAL ANALYSIS; PATENT; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SOCIAL ASPECT; SOCIAL CONTACT THEORY; THEORETICAL STUDY; THEORY;

EID: 3042650995     PISSN: 10546863     EISSN: None     Source Type: Journal    
DOI: 10.1353/ken.2004.0026     Document Type: Review

References (97)

1. Benowitz, Steve. 2002. French Challenge to BRCA1 Patent Underlies European Discontent [News]. Journal of the National Cancer Institute 94 (2): 80-81.
2. Bergmark, A. 2000. Solidarity in Swedish Welfare - Standing the Test of Time? Health Care Analysis 8: 395-411.
3. Birmingham, K. 1997. News: Myriad's Rationale for Wider Testing. Nature Medicine 3: 709.
4. Bloomfield, D.; Collins, K.; Fry, C.; and Munton, R. 1998. Deliberative and Inclusionary Processes: Their Contributions to Environmental Governance. Paper read at ESRC DIPs in Environmental Decisionmaking, 17 December.
5. Boorse, Christopher. 1975. On the Distinction between Disease and Illness. Philosophy & Public Affairs 5 (1): 49-68.
6. _. 1976. Wright on Functions. Philosophical Review 85 (1): 70-85.
7. _. 1977. Health as a Theoretical Concept. Philosophy of Science 44: 542-73.
8. Borger, Julian. 1999. Rush to Patent Genes Is Hampering Medical Research. The Guardian (15 December). Available at http://www.organicconsumers.org/ Patent/rushpatent.cfm. Accessed 20 April 2004.
9. British Columbia Ministry of Health Services. 2003. Federal Leadership Urged as Genetic Testing Resumes. Press Release (14 February). Available at http://www2.news.gov.bc.ca/nrm_news_releases/2003HSER0009-000160.htm. Accessed 20 April 2004.
10. Buchanan, Allen; Brock, Dan W.; Daniels, Norman; and Wikler, Daniel. 2000. From Chance to Choice: Genetics and Justice. New York: Cambridge University Press.
11. Burgess, Michael M., and d'Agincourt-Canning, Lori. 2002. Genetic Testing for Hereditary Disease: Attending to Relational Responsibility. Journal of Clinical Ethics 12: 361-72.
12. Burgess, Michael M., and Hayden, Michael R. 1996. Patients' Rights to Laboratory Data: Trinucleotide Repeat Length in Huntington Disease. American Journal of Medical Genetics 62: 6-9.
13. Canadian Cancer Society. 2003. Canadian Cancer Statistics. Available at http://www.cancer.ca/vgn/images/portal/cit_776/61/38/56158640niw_stats_en.pdf. Accessed 20 April 2004.
14. Canadian Institute for Health Information. 2003. Health Care in Canada, 2003. Available at http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_ page= PG_27_E&cw_topic=27&cw_rel=AR_43_ E. Accessed 20 April 2004.
15. Canadian Medical Association. 2003. CMA President Unveils a National Public Health Action Plan. Press Release (25 June). Available at http://www.cma.ca/cma/menu/displayMenu.do?tab=422&skin=432&pMenuId= 2&pSub MenuId=6&pageId=/staticContent/HTML/N0/l2/advocacy/news/2003/06- 25.htm. Accessed 20 April 2004.
16. Canadian Press. 2001. Ontario Defies U.S. Gene Company over Cancer Test, Arguing Health Care at Risk. Excite News (19 September). Available at http://lists.essential.org/pipermail/ip-health/2001-September/001885.html. Accessed 20 April 2004.
17. Caplan, Arthur. 1998. What's So Special About the Human Genome? Cambridge Quarterly of Healthcare Ethics 7: 422-24.
18. Carter, Ronald F. 2001. BRCA1, BRCA2 and Breast Cancer: A Concise Clinical Review. Clinical & Investigative Medicine 24 (3): 147-57.
19. Caulfield, Timothy A.; Burgess, Michael M.; Williams-Jones, Bryn; et al. 2001. Providing Genetic Testing through the Private Sector: A View from Canada. ISUMA: Canadian Journal of Policy Research 2 (3): 72-81.
20. CHEK2-Breast Cancer Consortium. 2002. Low-Penetrance Susceptibility to Breast Cancer Due to Chek2*1100delc in Noncarriers of BRCA1 or BRCA2 Mutations. Nature Genetics 31 (1): 55-59.
21. Cho, Mildred K.; Illangasekare, Samantha; Weaver, Meredith A.; et al. 2003. Effects of Patents and Licenses on the Provision of Clinical Genetic Testing Services. Journal of Molecular Diagnostics 5 (1): 3-8.
22. Col, Nananda F. 2003. The Use of Gene Tests to Detect Hereditary Predisposition to Chronic Disease: Is Cost-Effectiveness Analysis Relevant? Medical Decision Making 23: 441-48.
23. Goldman, Andrew J. 2001. Policy Change for Testing of Breast Cancer Susceptibility Genes: BRCA1 and BRCA2. Press Release (24 August), B.C. Cancer Agency.
24. Cox, Susan M., and McKellin, William. 1999. "There's This Thing in Our Family": Predictive Testing and the Construction of Risk for Huntington Disease. Sociology of Health & Illness 21: 622-46.
25. d'Agincourt-Canning, Lorraine. 2003. Advanced Warning: A Gift or a Yoke? Experiential Knowledge, Moral Agency and Genetic Testing for Hereditary Breast/Ovarian Cancer. Ph.D., Interdisciplinary Studies, University of British Columbia, Vancouver.
26. Daniels, Norman. 1985. Just Health Care. New York: Cambridge University Press.
27. _. 2001. Justice, Health, and Health Care. American Journal of Bioethics 1 (2): 2-16.
28. _, and Sabin, James. 1998. The Ethics of Accountability in Managed Care Reform. Health Affairs 17 (5): 50-64.
29. Deber, Raisa; Narine, Lutchmie; Baranek, Pat; et al. 1998. The Public-Private Mix in Health Care. In Striking a Balance: Health Care Systems in Canada and Elsewhere, ed. National Forum on Health, pp. 423-545. Sainte-Foy, QC: Éditions MultiMondes.
30. Department of Finance (Canada). 2003. Investing in Canada's Health Care System. 18 February. Available at http://www.fin.gc.ca/budget03/booklets/bkheae. htm. Accessed 20 April 2004.
31. Eggertson, Laura. 2002. Ontario Defies US Firm's Genetic Patent, Continues Cancer Screening. Canadian Medical Association Journal 166: 494.
32. Eisenberg, Rebecca S. 2002. How Can You Patent Genes? American Journal of Bioethics 2 (3): 3-11.
33. Emanuel, Ezekiel J. 2000. Justice and Managed Care: Four Principles for the Just Allocation of Health Care Resources. Hastings Center Report 30 (3): 8-16.
34. Evans, James P.; Skrzynia, Cécile; and Burke, Wylie. 2001. The Complexities of Predictive Testing. British Medical Journal 322: 1052-56.
35. Evans, Robert G. 2000. The Role of Private and Public Health Care Delivery in Alberta. Paper read at Health Forum, 5 February, Edmonton, AB.
36. _; Barer, Morris L.; Lewis, Steven; et al. 2000. Private Highway, One-Way Street: The Deklein and Fall of Canadian Medicare? Centre for Health Sciences and Policy Research, University of British Columbia, Vancouver, B.C., pp. 1-56. Available at http://www.chspr.ubc.ca/hpru/pdf/20003D.PDF. Accessed 20 April 2004.
37. _; Barer, Morris L. and Marmor, Theodore R., eds. 1994. Why Are Some People Healthy and Others Not? The Determinants of Health of Populations. New York: Aldine de Gruyter.
38. Flood, Colleen M. 1999. The Structure and Dynamics of Canada's Health Care System. In Canadian Health Law and Policy, ed. J. G. Downie and T. A. Caulfield, pp. 5-50. Toronto: Butterworths.
39. _, and Archibald, Tom. 2001. The Illegality of Private Health Care in Canada. Canadian Medical Association Journal 164: 825-30.
40. Frank, Thomas S.; Deffenbaugh, Amie M.; Reid, Julia E.; et al. 2002. Clinical Characteristics of Individuals with Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Journal of Clinical Oncology 20: 1480-90.
41. Giacomini, M.; Hurley, J.; and Stoddart, Greg L. 2000. The Many Meanings of Deinsuring a Health Service: The Case of In Vitro Fertilization in Ontario. Social Science & Medicine 50: 1485-1500.
42. Gollust, Sarah E.; Hull, Sara C.; and Wilfond, Benjamin S. 2002. Limitations of Direct-to-Consumer Advertising for Clinical Genetic Testing. JAMA 288: 1762-67.
43. Hallowell, N.; Foster, C.; Eeles, R.; et al. 2003. Balancing Autonomy and Responsibility: The Ethics of Generating and Disclosing Genetic Information. Journal of Medical Ethics 29 (2): 74-79. [Discussion follows on pp. 80-83.]
44. Hartmann, Lynn C.; Sellers, Thomas A.; Schaid, Daniel J.; et al. 2001. Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers. Journal of the National Cancer Institute 93: 1633-37.
45. Heller, Michael A., and Eisenberg, Rebecca S. 1998. Can Patents Deter Innovation? The Anticommons in Biomedical Research. Science 280: 698-701.
46. Holtzman, Neil A., and Shapiro, David. 1998. The New Genetics: Genetic Testing and Public Policy. British Medical Journal 316: 852-56.
47. Houtepen, R., and ter Meulen, R. T. 2000. The Expectation(s) of Solidarity: Matters of Justice, Responsibility and Identity in the Reconstruction of the Health Care System. Health Care Analysis 8: 355-76.
48. Hull, Sara C., and Prasad, Kiran. 2001. Reading Between the Lines: Direct-to-Consumer Advertising of Genetic Testing in the USA. Reproductive Health Matters 9 (18): 44-48.
49. Hutson, S. P. 2003. Attitudes and Psychological Impact of Genetic Testing, Genetic Counseling, and Breast Cancer Risk Assessment among Women at Increased Risk. Oncology Nursing Forum 30: 241-46.
50. Institut Curie. 2001. Against Myriad Genetics's Monopoly on Tests for Predisposition to Breast and Ovarian Cancer. 12 September. Available at http://www.curie.net/upload/presse/myriadopposition6sept01_gb.pdf. Accessed 20 April 2004.
51. Kaplan, George A.; Pamuk, Elsie R.; Lynch, John W.; et al. 1996. Inequality in Income and Mortality in the United States: Analysis of Mortality and Potential Pathways. British Medical Journal 312: 999-1003.
52. Kent, Heather. 2001a. Patenting Move Ends BC's Gene-Testing Program. Canadian Medical Association Journal 165: 812.
53. _. 2001b. Private PET-Scanning Clinic Opens in Vancouver. Canadian Medical Association Journal 164: 532.
54. King, Mary-Claire; Marks, Joan H.; and Mandell, Jessica B. 2003. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science 302: 643-46.
55. King, Mary-Claire; Wieand, Sam; Hale, Kathryn; et al. 2001. Tamoxifen and Breast Cancer Incidence among Women with Inherited Mutations in BRCA1 and BRCA2. JAMA 286: 2251-56.
56. Knoppers, Bartha Maria. 2000. Reflections: The Challenge of Biotechnology and Public Policy. McGill Law Journal 45: 559-66.
57. _; Hirtle, Marie; and Glass, Kathleen Cranley. 1999. Commercialization of Genetic Research and Public Policy. Science 286: 2277-78.
58. Koenig, Barbara A.; Greely, Henry T.; McConnell, L. M.; et al. 1998. Genetic Testing for BRCA1 and BRCA2: Recommendations of the Stanford Program in Genomics, Ethics, and Society. Journal of Women's Health 7: 531.
59. Krasner, Jeffrey. 2003. Marketing of Cancer-Gene Test Raises Ethical, Medical Concerns. The Boston Globe (26 March).
60. Lewens, Timothy. 2003. Health in Nature and Society. Presentation at Cambridge Bioethics Forum, King's College, Cambridge, June.
61. Lindgren, April. 2003. KGH to Use Disputed Gene Test for Cancer. Kingston Whig-Standard (7 January).
62. Lomas, Jonathan. 1997. Reluctant Rationers: Public Input to Health Care Priorities. Journal of Health Services & Research Policy 2 (2): 103-11.
63. Lynch, Henry T.; Lynch, Jane F.; and Rubinstein, Wendy S. 2001. Prophylactic Mastectomy: Obstacles and Benefits [Editorial]. Journal of the National Cancer Institute 93: 1586-87.
64. Mazankowski, Don. 2001. A Framework for Reform: Report of the Premier's Advisory Council on Health. December. Available at http://www.premiers advisory.com/reform.html. Accessed 20 April 2004.
65. McDaniels, Timothy L. 1998. Ten Propositions for Untangling Descriptive and Prescriptive Lessons in Risk Perception Findings. Reliability Engineering and System Safety 59 (1): 129-34.
66. McGee, Glenn. 1998. Gene Patents Can Be Ethical. Cambridge Quarterly of Healthcare Ethics 7: 417-21.
67. Mechanic, David. 1999. Issues in Promoting Health. Social Science & Medicine 48: 711-18.
68. Merz, Jon F.; Kriss, Antigone G.; Leonard, Debra G. B.; and Cho, Mildred K. 2002. Diagnostic Testing Fails the Test. Nature 415: 577-79.
69. Millstone, Erik. 2000. Analysing Biotechnology's Traumas. New Genetics & Society 19 (2): 117-132.
70. Moreno, Jonathan. 2002. Selling Genetic Tests: Shades of Gray in Your DNA. ABCNEWS.com. Available at http://abcnews.go.com/sections/living/DailyNews/ ONCALL_DTC_brca_tests020923.html. Accessed 20 April 2004.
71. Myriad Genetics. 2000a. Myriad Genetics Launches Colaris(Tm) in Canada: MDS to Market Colaris Colon Cancer Product Throughout Canada. Press Release (19 October). Available at http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker= mygn&script=411&layout-9&item_id=212127. Accessed 20 April 2004.
72. _. 2000b. Myriad Genetics Launches Molecular Diagnostic Testing in Canada-MDS Laboratory Services to Provide BRACAnalysis Throughout Canada. Press Release (9 March). Available at http://www.corporate-ir.net/ireye/ir_site.zhtml? ticker=mygn&script=411&layout=9&item_id=212154. Accessed 20 April 2004.
73. _. 2002. Myriad Genetics Launches Direct to Consumer Advertising Campaign for Breast Cancer Test. Press Release (12 September). Available at http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=mygn&script=411& layout=9&item_id=333030. Accessed 20 April 2004.
74. Narod, Steven A. 2002. Modifiers of Risk of Hereditary Breast and Ovarian Cancer. Nature Reviews Cancer 2: 113-123.
75. Nuffield Council on Bioethics. 2002. The Ethics of Patenting DNA: A Discussion Paper. July. Available at http://www.nuffieldbioethics.org/ filelibrary/pdf/theethicsofpatentingdna.pdf. Accessed 20 April 2004.
76. Ontario Ministry of Health and Long Term Care. 2002. Genetics, Testing & Gene Patenting: Charting New Territory in Healthcare. January. Available at http://www.health.gov.on.ca/english/public/pub/ministry_reports/ geneticsrep02/genetics.html. Accessed 20 April 2004.
77. Pinker, Susan. 2000. Private MRI Clinics Flourishing in Quebec. Canadian Medical Association Journal 163: 1326.
78. Prospero, Lisa; Seminsky, Maureen; Honeyford, Joanne; et al. 2001. Psychosocial Issues Following a Positive Result of Genetic Testing for BRCA1 and BRCA2 Mutations: Findings from a Focus Group and a Needs-Assessment Survey. Canadian Medical Association Journal 164: 1005-9.
79. Rahko, E.; Blanco, G.; Soini, Y.; et al. 2003. A Mutant Tp53 Gene Status Is Associated with a Poor Prognosis and Anthracycline-Resistance in Breast Cancer Patients. European Journal of Cancer 39: 447-53.
80. Rawls, John. 1971. A Theory of Justice. Cambridge, MA: Belknap Press.
81. Renn, Ortwin; Webler, Thomas; and Wiedemann, Peter; eds. 1995. Fairness and Competence in Citizen Participation: Evaluating Models for Environmental Discourse. London: Kluwer Academic Publishers.
82. Robson, Mark E. 2002. Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer. Cancer Control 9: 457-65.
83. Romanow, Roy J. 2002. Final Report: Building on Values: The Future of Health Care in Canada. 28 November. Available at http://www.hc-sc.gc.ca/english/ care/romanow/index1.html. Accessed 20 April 2004.
84. Royal Society. 2003. Keeping Science Open: The Effects of Intellectual Property Policy on the Conduct of Science. April. Available at http://www.royalsoc. ac.uk/files/statfiles/document-221.pdf. Accessed 20 April 2004.
85. Scheuer, Lauren; Kauff, Noah; Robson, Mark; et al. 2002. Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. Journal of Clinical Oncology 20: 1260-68.
86. Secretary's Advisory Committee on Genetic Testing. 2000. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT. Available at http://www4.od.nih.gov/oba/sacgt/reports/oversight_report.pdf. Accessed 20 April 2004.
87. Sevilla, C.; Julian-Reynier, C.; Eisinger, F.; et al. 2003. Impact of Gene Patents on the Cost-Effective Delivery of Care: The Case of BRCA1 Genetic Testing. International Journal of Technology Assessment in Healthcare 19: 287-300.
88. Sherwin, Susan. 1996. Theory Versus Practice in Ethics: A Feminist Perspective on Justice in Health Care. In Philosophical Perspectives on Bioethics, ed. L. W. Sumner and J. Boyle, pp. 187-209. Toronto: University of Toronto Press.
89. _. 2001. Towards an Adequate Ethical framework for Setting Biotechnology Policy. January. Available at http://cbac-cccb.ca/epic/internet/incbac-cccb.nsf/ vwapj/BioPolicy_Sherwin_e.pdf/$FILE/BioPolicy_Sherwin_e.pdf. Accessed 20 April 2004.
90. Smith, O. 1997. News: Breast Cancer Susceptibility Tests Still Valid, Companies Argue. Nature Medicine 3: 709.
91. Szabo, Csilla I., and King, Mary-Claire 1997. Population Genetics of BRCA1 and BRCA2. American Journal of Human Genetics 60: 1013-20.
92. Thompson, Deborah; Szabo, Csilla I.; Mangion, Jon; et al. 2002. From the Cover: Evaluation of Linkage of Breast Cancer to the Putative BRCA3 Locus on Chromosome 13q21 in 128 Multiple Case Families from the Breast Cancer Linkage Consortium. Proceedings of the National Academy of Sciences of the United States of America 99: 827-31.
93. Wertz, Dorothy C., and Gregg, Robin. 2000. Genetics Services in a Social, Ethical and Policy Context: A Collaboration Between Consumers and Providers. Journal of Medical Ethics 26: 261-65.
94. Williams-Jones, Bryn. 2002a. Genetic Testing for Sale: Implications of Commercial BRCA Testing in Canada. Ph.D., Individual Interdisciplinary Studies Graduate Program, University of British Columbia, Vancouver, B.C.
95. _. 2002b. History of a Gene Patent: Tracing the Development and Application of Commercial BRCA Testing. Health Law Journal 10: 121-44.
96. _. 2003. Where There's a Web, There's a Way: Commercial Genetic Testing and the Internet. Community Genetics 6 (1): 46-57.
97. _, and Graham, Janice E. 2003. Actor-Network Theory: A Tool to Support Ethical Analysis of Commercial Genetic Testing. New Genetics & Society 22: 271-96.